Ge Long Hui A P P·2026-01-25 23:22Core Viewpoint - The company, China National Pharmaceutical Group (国药控股), announced that its subsidiary, China National Pharmaceutical Group Co., Ltd. (国药一致), expects a significant increase in net profit for the fiscal year 2025, despite anticipated asset impairment losses [1] Financial Performance - The company forecasts a net profit attributable to shareholders ranging from 1.055 billion to 1.215 billion yuan for 2025, representing a year-on-year growth of 64.20% to 89.11% [1] - The expected net profit, excluding non-recurring gains and losses, is projected to be between 996 million and 1.156 billion yuan, indicating an increase of 71.38% to 98.91% compared to the previous year [1] Asset Impairment - The company plans to recognize goodwill and intangible asset impairment losses between 240 million and 330 million yuan for 2025, which is a decrease of 639.9 million to 729.9 million yuan from the previous year [1] Strategic Direction - The company aims to continue its strategic transformation and refined management practices to consolidate operational results and enhance core competitiveness, focusing on sustainable and high-quality development [1]